
Lakdawala and Vernon’s session discusses the changing landscape of hormonal contraception and pharmacists’ roles within it.

Lakdawala and Vernon’s session discusses the changing landscape of hormonal contraception and pharmacists’ roles within it.

The data comes from 2 phase 4 trials, ENABLE and EMPOWER, which evaluated lanadelumab and the outcomes of treatment in adolescents with hereditary angioedema.

Nazia Somani Babul, PharmD, BCACP, discussed her presentation about nontraditional pharmacy models, and particularly a model at her facility focused on comprehensive pain management counseling.

Mila Felder, MD, FACEP, discusses Advocate Aurora Health’s approach to addressing burnout among health care professionals in health care systems.

Women who have longer ovarian function and enter menopause later in life tend to live longer, according to women’s health researcher.

The findings suggest that ruxolitinib cream could aid itch, pain, and sleep disturbance.

This treatment improved the severity of symptoms in patients with scalp and nail psoriasis.

Findings originate from phase 3 data that was recently presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting.

The cream significantly reduced abscesses and inflammatory nodules, reaffirming its efficacy as a maintenance option for HS.

Health span, wealth span, advocacy, and ethics are all burgeoning topics within the field of longevity.

Secukinumab affects levels of inflammatory biomarkers, and monitoring levels can help investigators understand how patients are responding to treatment.

In addition, the length of hospital admissions were greater in patients with hidradenitis suppurativa-associated cutaneous squamous cell carcinoma compared to other admissions.

The biosimilarity was evident between SB17 (Samsung Bioepis), ustekinumab (Stelara; Janssen Immunology), and those switching from ustekinumab to SB17.

The CORe initiative is aimed at promoting inclusivity, reducing startup time for clinical trials, and facilitating data sharing to address recruitment and retention challenges in cancer research at community oncology sites.

Although regulation takes time, real safety concerns for patients in the rapid development of AI technology in health care are present today.

Although cancer death rates have decreased in the United States overall, they continue to rise in rural Appalachia, engendering a malaise of fatalism in the region.

Will Shapiro, vice president of Data Science at Flatiron Health, provides context into the terminology and history of these models.

The ACCC 50th Annual Meeting & Cancer Center Business Summit is taking place in Washington, DC from February 28 to March 1.

Compared to embolization alone, the systemic treatment combination nearly doubled progression-free survival among patients with unresectable liver cancer.

pCR rates improve regardless of whether patients received full chemotherapy doses.

Radioligands may be able to deliver radiation to advanced tumor cells anywhere in the body.

No established standard of care currently exists after spread to the lymph nodes.

Compared to TACE alone, durvalumab plus TACE and bevacizumab reduced the risk of disease progression or death by 23%; however, further research is needed to assess OS.

The combination resulted in numerically longer OS compared with an NSAI alone.

The MRD-guided treatment approach has a significant advantage over chemotherapy.

It can also help identify patients who would benefit from disease-specific therapies.

Data support the quadruplet regimen as a new standard of care for transplant-eligible patients.

Public Health Pharmacist discussed wearable technology and AI assisted technology that was displayed at the 2024 Consumer Electronics Show

Significant study results could inform clinical practice strategies.

Presentations detail clinical trial results and focus on drugs in the pipeline.